Sangamo BioSciences | SGMO - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Alaunos Therapeutics USD 2.49M 108K 2026-06
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
Amgen USD 541M 0 2026-09
Bayer EUR 982.42M 0 2026-09
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Cipla INR 807.87M 88K 2026-09
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.72M 170K 2026-06
CSL USD 482.13M 93.87M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Grifols EUR 680.58M 846.11K 2025-12
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.64M 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Merck USD 2.47B 1.05M 2026-06
Novartis USD 1.89B 12.09M 2026-09
Omeros USD 611K 17K 2023-12
Pfizer USD 5.7B 0 2026-06
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.2B 0 2026-09
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Tectonic Therapeutic USD 19.24M 404.78K 2026-06
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09